Enthera Pharmaceuticals raised a total financing of €35 million from Roche Venture Fund, Sofinnova Partners and AbbVie Ventures

Switzerland Italy United States Investments 28 January 2021
Share on FacebookShare on Twitter

Enthera Pharmaceuticals, a Milan, Italy-based biotech company developing disease-modifying biologics, announced securing a total financing of €35 million ($42.4M).

The money was rasied from The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures.

Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.

Enthera Pharmaceuticals was in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio.

The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund.

A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.